Gilead Collaborates with Merus For Novel Antibody-Based Trispecific T-Cell Engagers
By Lalit Mishra
Pharma Deals Review: Vol 2024 Issue 3 (Table of Contents)
Published: 22 Mar-2024
DOI: 10.3833/pdr.v2024.i3.2861 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In order to strengthen its oncology portfolio, Gilead Sciences has entered into a research collaboration, option and license agreement with Merus to discover novel dual tumour-associated antigens (TAA)-targeting trispecific antibodies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS